JP2023551355A5 - - Google Patents
Info
- Publication number
- JP2023551355A5 JP2023551355A5 JP2023520181A JP2023520181A JP2023551355A5 JP 2023551355 A5 JP2023551355 A5 JP 2023551355A5 JP 2023520181 A JP2023520181 A JP 2023520181A JP 2023520181 A JP2023520181 A JP 2023520181A JP 2023551355 A5 JP2023551355 A5 JP 2023551355A5
- Authority
- JP
- Japan
- Prior art keywords
- here
- group
- ring
- independently
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011061580 | 2020-09-30 | ||
| CN202011061580.7 | 2020-09-30 | ||
| PCT/CN2021/121721 WO2022068878A1 (zh) | 2020-09-30 | 2021-09-29 | 一种抗肿瘤化合物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551355A JP2023551355A (ja) | 2023-12-08 |
| JP2023551355A5 true JP2023551355A5 (https=) | 2024-10-08 |
Family
ID=80951198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520181A Pending JP2023551355A (ja) | 2020-09-30 | 2021-09-29 | 抗腫瘍化合物並びにその調製方法及び使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US11685742B2 (https=) |
| EP (2) | EP4223318A4 (https=) |
| JP (1) | JP2023551355A (https=) |
| KR (1) | KR20230079085A (https=) |
| CN (5) | CN121944137A (https=) |
| AU (1) | AU2021354823A1 (https=) |
| CA (1) | CA3195515A1 (https=) |
| DK (1) | DK4516357T3 (https=) |
| FI (1) | FI4516357T3 (https=) |
| IL (1) | IL301793A (https=) |
| LT (1) | LT4516357T (https=) |
| MX (1) | MX2023003778A (https=) |
| TW (1) | TW202214230A (https=) |
| WO (1) | WO2022068878A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023551355A (ja) * | 2020-09-30 | 2023-12-08 | デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド | 抗腫瘍化合物並びにその調製方法及び使用 |
| GEAP202416409A (en) | 2021-05-07 | 2024-02-26 | Alx Oncology Inc | Exatecan derivatives and antibody-drug conjugates thereof |
| CN115557962A (zh) * | 2021-07-02 | 2023-01-03 | 石药集团巨石生物制药有限公司 | 新型喜树碱类化合物及其制备方法和应用 |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CN115850291B (zh) * | 2021-09-24 | 2024-11-15 | 石药集团巨石生物制药有限公司 | 喜树碱衍生物及其用途 |
| US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| CN118829450A (zh) * | 2022-01-18 | 2024-10-22 | 甘李药业股份有限公司 | 一种依喜替康衍生物-抗体偶联物及其医药用途 |
| TW202341984A (zh) * | 2022-01-28 | 2023-11-01 | 大陸商映恩生物製藥（蘇州）有限公司 | Ｈｅｒ３抗體藥物偶聯物及其用途 |
| EP4489790A1 (en) * | 2022-03-10 | 2025-01-15 | Vivasor, Inc. | Antibody-drug conjugates and uses thereof |
| WO2023174401A1 (zh) * | 2022-03-18 | 2023-09-21 | 映恩生物制药（苏州）有限公司 | Gpc3抗体药物偶联物及其用途 |
| CN118696048A (zh) * | 2022-05-09 | 2024-09-24 | 同宜医药（苏州）有限公司 | 一种喜树碱衍生物，基于其的抗体-药物偶联物和药物组合物，及其应用 |
| JP2025515988A (ja) * | 2022-05-13 | 2025-05-23 | シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド | カンプトテシン化合物、その調製方法及びその使用 |
| CN119384296A (zh) * | 2022-06-07 | 2025-01-28 | 映恩生物制药（苏州）有限公司 | 抗b7h3抗体-药物偶联物及其用途 |
| IL318296A (en) | 2022-07-15 | 2025-03-01 | Genequantum Healthcare Suzhou Co Ltd | Anti-TROP2 antibody and its conjugate |
| EP4562051A1 (en) * | 2022-07-26 | 2025-06-04 | Immunome, Inc. | Immunoconjugates and methods |
| JP2025526504A (ja) * | 2022-07-29 | 2025-08-13 | 杭州愛科瑞思生物医薬有限公司 | エキサテカン誘導体及びその使用 |
| US20240116945A1 (en) * | 2022-09-02 | 2024-04-11 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
| KR20250069963A (ko) * | 2022-09-30 | 2025-05-20 | 베이진 스위찰랜드 게엠베하 | 엑사테칸 유사체의 리간드-약물 접합체 및 이의 의학적 용도 |
| WO2024078449A1 (en) * | 2022-10-09 | 2024-04-18 | LaNova Medicines Limited | Compounds, compositions and methods |
| WO2024091437A1 (en) * | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| WO2024098066A1 (en) * | 2022-11-04 | 2024-05-10 | ALX Oncology Inc. | Exatecan derivatives and antibody-drug conjugates thereof |
| CN119855820A (zh) * | 2022-12-16 | 2025-04-18 | 上海齐鲁制药研究中心有限公司 | 喜树碱类化合物及其制备方法和用途 |
| CN119947761B (zh) * | 2022-12-27 | 2026-03-03 | 映恩生物科技(上海)有限公司 | 抗b7h3和pd-l1的双特异性抗体药物偶联物及其制备方法和用途 |
| AU2023417911A1 (en) * | 2022-12-28 | 2025-05-29 | Adcendo Aps | Antibody-drug conjugates targeting uparap comprising exatecan derivatives |
| CN116712561A (zh) * | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | 含n-亚甲基酰胺连接子的抗体-药物偶联物 |
| WO2024193692A1 (zh) | 2023-03-22 | 2024-09-26 | 映恩生物制药（苏州）有限公司 | 连接子及其在配体药物偶联物中的应用 |
| JPWO2024214685A1 (https=) | 2023-04-10 | 2024-10-17 | ||
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| WO2025031286A1 (zh) * | 2023-08-04 | 2025-02-13 | 映恩生物制药（苏州）有限公司 | 抗体药物偶联物的识别抗体及其应用 |
| WO2025166725A1 (en) | 2024-02-08 | 2025-08-14 | Duality Biologics (Suzhou) Co., Ltd. | Antibody-drug conjugate |
| AR133816A1 (es) | 2023-09-15 | 2025-11-05 | Duality Biologics Suzhou Co Ltd | Conjugado anticuerpo-fármaco |
| WO2025054996A1 (en) | 2023-09-15 | 2025-03-20 | Duality Biologics (Suzhou) Co., Ltd. | Antibody-drug conjugate |
| CN117417347A (zh) * | 2023-09-28 | 2024-01-19 | 杭州爱科瑞思生物医药有限公司 | 卤素取代的依沙替康的酰胺衍生物及其制备方法和应用 |
| WO2025106278A1 (en) | 2023-11-17 | 2025-05-22 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
| WO2025162049A1 (zh) * | 2024-02-02 | 2025-08-07 | 长春金赛药业有限责任公司 | 卤代烯烃类喜树碱衍生物、药物组合物及其制备方法和应用 |
| WO2025238587A1 (en) | 2024-05-16 | 2025-11-20 | Daiichi Sankyo Company, Limited | Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor |
| WO2025247255A1 (zh) * | 2024-05-28 | 2025-12-04 | 映恩生物科技(上海)有限公司 | 一种抗dll3抗体、抗体药物偶联物及其应用 |
| WO2025247302A1 (zh) * | 2024-05-31 | 2025-12-04 | 杭州中美华东制药有限公司 | 一种喜树碱类化合物及其应用 |
| WO2025252101A1 (zh) * | 2024-06-05 | 2025-12-11 | 荣昌生物制药(烟台)股份有限公司 | 一种喜树碱类化合物及其用途 |
| WO2025256761A1 (en) | 2024-06-14 | 2025-12-18 | BioNTech SE | Combination therapy for cancer treatment |
| WO2025257394A1 (en) | 2024-06-14 | 2025-12-18 | BioNTech SE | Combination therapy for cancer treatment |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| EA003398B1 (ru) * | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Лекарственный комплекс c полимерным носителем |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| WO2014061277A1 (ja) * | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| IL310627B2 (en) * | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| EP3130608B1 (en) * | 2014-04-10 | 2019-09-04 | Daiichi Sankyo Co., Ltd. | (anti-her2 antibody)-drug conjugate |
| KR20190066026A (ko) * | 2016-10-07 | 2019-06-12 | 다이이찌 산쿄 가부시키가이샤 | 항 her2 항체-약물 콘주게이트 투여에 의한 내성암의 치료 |
| WO2019034176A1 (zh) | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| CN110016026B (zh) * | 2018-01-08 | 2022-11-25 | 上海凌济生物科技有限公司 | 一类具有抗肿瘤活性的嘧啶并吡啶酮类化合物、制备方法和用途 |
| WO2020063676A1 (zh) * | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
| CA3114474A1 (en) * | 2018-09-30 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof |
| CN113260384A (zh) | 2018-11-05 | 2021-08-13 | 西纳福克斯股份有限公司 | 用于靶向表达trop-2的肿瘤的抗体缀合物 |
| CN111689980A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种喜树碱药物及其抗体偶联物 |
| MX2022000449A (es) * | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| CN112125915A (zh) | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
| CN116390771A (zh) * | 2020-07-13 | 2023-07-04 | 瑞泽恩制药公司 | 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途 |
| JP2023551355A (ja) * | 2020-09-30 | 2023-12-08 | デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド | 抗腫瘍化合物並びにその調製方法及び使用 |
| WO2022078279A1 (zh) | 2020-10-12 | 2022-04-21 | 昆山新蕴达生物科技有限公司 | 抗体-药物偶联物及其应用 |
| US20250276078A1 (en) | 2020-10-12 | 2025-09-04 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Camptothecin Derivative And Ligand-drug Conjugate Thereof |
| CN114569739A (zh) | 2020-12-01 | 2022-06-03 | 正大天晴药业集团股份有限公司 | 抗体药物偶联物 |
| EP4628165A3 (en) | 2021-02-05 | 2026-03-11 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
| CN113816969B (zh) | 2021-04-30 | 2024-01-16 | 联宁（苏州）生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
| GEAP202416409A (en) | 2021-05-07 | 2024-02-26 | Alx Oncology Inc | Exatecan derivatives and antibody-drug conjugates thereof |
-
2021
- 2021-09-29 JP JP2023520181A patent/JP2023551355A/ja active Pending
- 2021-09-29 EP EP21874533.9A patent/EP4223318A4/en active Pending
- 2021-09-29 KR KR1020237011470A patent/KR20230079085A/ko active Pending
- 2021-09-29 AU AU2021354823A patent/AU2021354823A1/en active Pending
- 2021-09-29 MX MX2023003778A patent/MX2023003778A/es unknown
- 2021-09-29 IL IL301793A patent/IL301793A/en unknown
- 2021-09-29 LT LTEP24204055.8T patent/LT4516357T/lt unknown
- 2021-09-29 TW TW110136259A patent/TW202214230A/zh unknown
- 2021-09-29 WO PCT/CN2021/121721 patent/WO2022068878A1/zh not_active Ceased
- 2021-09-29 CN CN202610025967.8A patent/CN121944137A/zh active Pending
- 2021-09-29 DK DK24204055.8T patent/DK4516357T3/da active
- 2021-09-29 CN CN202180018263.3A patent/CN115175705B/zh active Active
- 2021-09-29 CN CN202211407530.9A patent/CN115925796B/zh active Active
- 2021-09-29 FI FIEP24204055.8T patent/FI4516357T3/fi active
- 2021-09-29 CN CN202310152789.1A patent/CN116239601B/zh active Active
- 2021-09-29 CN CN202211403184.7A patent/CN116199739B/zh active Active
- 2021-09-29 EP EP24204055.8A patent/EP4516357B1/en active Active
- 2021-09-29 CA CA3195515A patent/CA3195515A1/en active Pending
-
2022
- 2022-05-26 US US17/825,090 patent/US11685742B2/en active Active
- 2022-05-31 US US17/828,433 patent/US11607459B1/en active Active
- 2022-12-28 US US18/147,070 patent/US11952384B2/en active Active
-
2023
- 2023-03-22 US US18/187,935 patent/US12434077B2/en active Active
- 2023-10-26 US US18/495,455 patent/US12091418B2/en active Active
- 2023-11-10 US US18/506,610 patent/US12168667B2/en active Active
-
2025
- 2025-08-04 US US19/289,628 patent/US20250367316A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023551355A5 (https=) | ||
| JP7551056B2 (ja) | プログラマブルなポリマー薬物 | |
| JP7403744B2 (ja) | プログラマブルな樹枝状薬物 | |
| Drewry et al. | Solid-phase synthesis of trisubstituted guanidines | |
| JP2021503450A (ja) | プログラム可能なポリマー薬 | |
| CN111565757A (zh) | 包含生物活性化合物的磷酸烷基聚合物 | |
| AU2013231819B2 (en) | Aminoacid lipids | |
| CN111565756A (zh) | 包含生物活性化合物的具有刚性间隔基团的聚合物 | |
| KR20200098618A (ko) | 생물학적 활성 화합물을 함유하는 이온성 중합체 | |
| JP7304128B2 (ja) | 白金耐性の克服における使用のためのテキサフィリン－白金（ｉｖ）コンジュゲート及び組成物 | |
| US8962838B2 (en) | Platinum complexes and their use | |
| AU2022252848B2 (en) | Macrocyclic ligands with pendant chelating moieties and complexes thereof | |
| JP2008517949A5 (https=) | ||
| JP2024537069A (ja) | ポリマーデュアル薬物の自動合成 | |
| AU2018317611B2 (en) | Non-natural amatoxin-type antibody conjugate | |
| US20040142851A1 (en) | Hydrazinopeptoids and their uses for treating cancers | |
| CA2891593A1 (en) | Di-macrocycles | |
| ES2947326T3 (es) | Procedimiento de producción de un derivado de imidazo[1,2-b]piridazina 3,6-disubstituido | |
| CN105440059B (zh) | 氨基酸与邻菲啰啉或其衍生物的铜配合物及其制备方法和应用 | |
| JP2006520360A (ja) | シクロブタン−１，１−ジカルボキシレートリガンドを有する白金錯体の蛋白結合誘導体 | |
| NL2020120B1 (en) | Methods for preparing cell targeting conjugates and conjugates obtainable by said methods | |
| CN104672213A (zh) | 一种具有抗肿瘤活性的酰胺类化合物及其应用 | |
| US12304920B2 (en) | Platinum complex, its preparation and therapeutic use | |
| TW202535475A (zh) | 包含喜樹鹼衍生物之抗ｃ－Ｍｅｔ抗體－藥物綴合物 | |
| KR20250168470A (ko) | 캄프토테신 유도체의 항체-약물 접합체 및 이의 용도 |